|1.||Schwartz, Jonathan D: 9 articles (09/2015 - 12/2013)|
|2.||Abdel-Rahman, Omar: 5 articles (11/2015 - 01/2014)|
|3.||Chau, Ian: 5 articles (11/2015 - 01/2014)|
|4.||Joshi, Adarsh: 5 articles (09/2015 - 12/2013)|
|5.||ElHalawani, Hesham: 4 articles (11/2015 - 01/2014)|
|6.||Hozak, Rebecca R: 4 articles (09/2015 - 12/2013)|
|7.||Gao, Ling: 4 articles (07/2015 - 01/2014)|
|8.||Yurasov, Sergey: 4 articles (03/2015 - 11/2012)|
|9.||Aprile, Giuseppe: 4 articles (01/2014 - 05/2013)|
|10.||Yang, Ling: 3 articles (09/2015 - 10/2014)|
12/01/2013 - "REGARD was the first phase III study to report on the efficacy of single-agent ramucirumab in patients with advanced cancer. "
06/01/2015 - "An initial phase I study evaluated ramucirumab administered weekly in advanced cancer patients. "
01/01/2014 - "Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial."
01/01/2012 - "Many Ab molecules directly or indirectly targeting angiogenesis have been identified, and one of them, ramucirumab, has been tested in 27 phase I-III clinical trials in a broad array of cancers. "
04/01/2011 - "Ramucirumab is currently being investigated in multiple clinical trials across a variety of tumor types. "
|2.||Stomach Neoplasms (Stomach Cancer)
12/01/2014 - "The recent REGARD trial was a randomized phase III trial of ramucirumab vs. placebo for patients with advanced, pretreated gastric cancer that met its primary endpoint of increased overall survival. "
08/01/2013 - "Most recently, the large Phase III REGARD trial evaluated ramucirumab in patients with refractory metastatic gastric cancer. "
10/01/2015 - "Ramucirumab: A Review in Advanced Gastric Cancer."
08/01/2015 - "FDA Approval Summary: Ramucirumab for Gastric Cancer."
07/01/2015 - "Ramucirumab (Cyramza): A breakthrough treatment for gastric cancer. "
01/01/2014 - "The international phase III REGARD study demonstrated improved overall survival with ramucirumab as second-line therapy for patients with advanced-stage gastric and gastroesophageal junction adenocarcinoma. "
01/04/2014 - "Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial."
01/01/2014 - "Ramucirumab, an anti-VEGFR-2 antibody, has been recently evaluated in the large Phase III REGARD trial, demonstrating a significant survival benefit in second-line treatment of patients with advanced gastric or gastro-eosophageal junction adenocarcinoma. "
06/01/2015 - "Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma."
01/04/2014 - "Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
05/01/2015 - "Ramucirumab plus FOLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma. "
04/01/2014 - "An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer."
09/01/2015 - "Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?"
07/01/2015 - "Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma."
01/01/2015 - "Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice."
|5.||Breast Neoplasms (Breast Cancer)
08/20/2015 - "Just Toxicity, or Toxicity As a Biomarker of Efficacy of Ramucirumab in Breast Cancer?"
09/01/2014 - "Clinical experience with ramucirumab : outcomes in breast cancer."
04/01/2014 - "The Phase III trial in patients with advanced breast cancer failed to improve the primary end point The REGARD trial, a Phase III study, in patients with advanced gastric cancer in the second line setting, had a marginal improvement in overall survival but did not achieve the expected hazard ratio target (of 0.69) and the median duration of therapy with ramucirumab was meager 8 weeks (only 2 weeks longer than the placebo's). "
01/10/2015 - "The ROSE/TRIO-012 trial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast cancer. "
09/01/2014 - "This article will review the preclinical data available to date for ramucirumab, as well as survey the main clinical trials of antiangiogenic agents reported in breast cancer, focusing on Phase III clinical trials. "
|1.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||sorafenib (BAY 43-9006)
|9.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)